Dr. Mark S. Lee, M.D.
Dermatology (Dermatology Physician)
At a glance
- In the NPI registry since
- 2006
Licensed in Texas since 1995, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Dermatology Physician primary
TX license J7551 (first issued 1995; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Payments from drug and device companies
In 2025, 3 companies reported 31 payments worth $4,730 in total to this clinician.
| Takeda Pharmaceuticals U.S.A., Inc. | $3,615 |
|---|---|
| Merck Sharp & Dohme LLC | $1,096 |
| Lilly USA, LLC | $19.36 |
| Travel and Lodging | $3,697 |
|---|---|
| Food and Beverage | $1,033 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. Oct 10, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $652 |
| Merck Sharp & Dohme LLC Apr 30, 2025 | Travel and Lodging IMMUNOLOGY · travel to Houston, TX · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $533 |
| Takeda Pharmaceuticals U.S.A., Inc. Jun 26, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $443 |
| Takeda Pharmaceuticals U.S.A., Inc. Jun 26, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $316 |
| Takeda Pharmaceuticals U.S.A., Inc. Jun 27, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $288 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 9, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $252 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 10, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $252 |
| Takeda Pharmaceuticals U.S.A., Inc. Jun 26, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $248 |
| Merck Sharp & Dohme LLC Apr 30, 2025 | Travel and Lodging IMMUNOLOGY · travel to Houston, TX · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $228 |
| Merck Sharp & Dohme LLC Apr 30, 2025 | Travel and Lodging IMMUNOLOGY · travel to Houston, TX · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $180 |
All 13 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. Nov 24, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $11.34 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 10, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $652 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 10, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $252 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 10, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $114 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 9, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $252 |
| Takeda Pharmaceuticals U.S.A., Inc. Oct 8, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $180 |
| Takeda Pharmaceuticals U.S.A., Inc. Jun 27, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $288 |
| Takeda Pharmaceuticals U.S.A., Inc. Jun 26, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $443 |
| Takeda Pharmaceuticals U.S.A., Inc. Jun 26, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $316 |
| Takeda Pharmaceuticals U.S.A., Inc. Jun 26, 2025 | Travel and Lodging travel to CHICAGO, IL · in-kind | $248 |
| Merck Sharp & Dohme LLC Apr 30, 2025 | Travel and Lodging IMMUNOLOGY · travel to Houston, TX · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $533 |
| Merck Sharp & Dohme LLC Apr 30, 2025 | Travel and Lodging IMMUNOLOGY · travel to Houston, TX · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $228 |
| Merck Sharp & Dohme LLC Apr 30, 2025 | Travel and Lodging IMMUNOLOGY · travel to Houston, TX · in-kind Company’s descriptionProvided as part of a clinical research engagement. | $180 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 37 industry-funded studies in 2025, from 9 companies. The companies reported $1,512,357 in research payments for these studies, mostly to the institutions running them.
- Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
Eli Lilly and Company · Completed · NCT06588283 - A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopi…
Janssen Research & Development, LLC - TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis
Takeda Pharmaceuticals U.S.A., Inc. - A study about how well TAK-279 works and its safety in participants with moderate-to-severe plaque psoriasis during 52 weeks of treatment
Takeda Pharmaceuticals U.S.A., Inc. - TAK-279-PsO-3004 A Phase 3, multi-center, head to head Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis
Takeda Pharmaceuticals U.S.A., Inc. - A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis
Sun Pharmaceutical Industries Inc. - A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of lebrikizumab in adult and adolescent participants with moderate-to-severe atopic hand and foot d…
Eli Lilly and Company - A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderat…
Janssen Research & Development, LLC - A Study to Investigate Improvement in Pruritus of Lichen Simplex Chronicus With Dupilumab Injections Compared With Placebo in Male and Female Participants Aged at Least 18 Years (STYLE 2)
Sanofi US Services Inc. · Completed · NCT06687980 - Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM)
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.